Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

4867 Pages (Click to Jump) V   1 2 3 4 > »    
 
  
Reply to this topic

CUV, CLINUVEL PHARMACEUTICALS LIMITED
CobiV13
post Posted: Yesterday, 11:35 PM
  Quote Post


Posts: 32
Thanks: 21


In Reply To: royco's post @ Jan 16 2020, 06:04 PM

How long more Will they allow this rogue outfit to go on? Probably until there is enough public pressure demanding a cancer preventying solution. Cancer associatiions should be fighting this fiight for us but they don't know



Said 'Thanks' for this post: royco  
 
LegendInMySpareT...
post Posted: Yesterday, 09:49 PM
  Quote Post


Posts: 9
Thanks: 21


In Reply To: PunkassDerm's post @ Yesterday, 02:01 PM

Hey PAD, what's your take on recent developments with PTN/AMAG? PTN still worth a shot in your opinion?

 
seeva222
post Posted: Yesterday, 06:21 PM
  Quote Post


Posts: 1,444
Thanks: 1619


In Reply To: polyphemus's post @ Yesterday, 01:01 PM

It was written in obfuscation

Reminded me of my college papers.

 
johnnytech
post Posted: Yesterday, 02:36 PM
  Quote Post


Posts: 474
Thanks: 994


More shorts. We are now up to 7.56% total. It seems like nearly every day for the past week a new all-time high is established. Compare this to 5.6% on day of FDA approval. And it meandered around up to 6.5% for a bit, but since December 20th it's shot past 7% and has been green upticks non-stop since then.

The upside is the stock price keeps hovering around the same and slightly upticking. The shorters are having to run harder and harder to stand still.


Said 'Thanks' for this post: royco  Farleap11  xlnja  KRD  
 
PunkassDerm
post Posted: Yesterday, 02:01 PM
  Quote Post


Posts: 550
Thanks: 1507


SYN-ER-GIES
Move it Wolgen!

Part of my regenerative medicine fund.

In the meantime I'm gonna sell a little more, live a little more. Still have lots to ride on.


https://stockhead.com.au/health/dr-borehams...sion-ambitions/

Dr Boreham’s Crucible: Avita in for a busy 2020 with big expansion ambitions


‘White leprosy’

But wait, there’s more: Avita is in early stage work with vitiligo, the genetic disorder that results in loss of pigmentation and skin turning white.

It’s also known as white leprosy or the Michael Jackson disease.

“We have treated 1,000 patients in China, we know it works,” Dr Perry says.

The company cites an addressable market of $US750m to $US1 billion.

In the US, Dr Perry says, 150,000 vitiligo patients are currently seeking therapy, but there are 6.5 million sufferers in all. “The reason there’s so few (seeking treatment) is that there’s nothing on the market currently to restore pigment to its original color and texture,” he says. (Clinuvel is working on it.)


Said 'Thanks' for this post: odi01  royco  xlnja  
 
KRD
post Posted: Yesterday, 01:33 PM
  Quote Post


Posts: 1,144
Thanks: 1696


In Reply To: polyphemus's post @ Yesterday, 01:01 PM

Hard read was an understatement. Virtually no new details on any of the items of interest reported. They’ve been talking up a new indication and OTC product(s) for what 2 years? Is the PH 3 vitiligo trial starting in 2020 or 2021? How about at least a comment on progress with US reimbursement (BCBS)? Or does this information only get shared with the heavy hitter investor groups behind closed doors?


Said 'Thanks' for this post: PunkassDerm  xlnja  Frogster  endymion96  odi01  macgyver  simon_vienna  
 

sentifi.com

Share Cafe Sentifi Top themes and market attention on:


polyphemus
post Posted: Yesterday, 01:01 PM
  Quote Post


Posts: 525
Thanks: 802


In Reply To: mattho's post @ Yesterday, 05:56 AM

The communique really was a hard read.
I preferred last years. It had a lot of detail on
FDA PDUFA details,
Vitiligo update,
VP update with trial CUV040 likely to start in 2019,
New Indication just needing ethics, funding and protocols to be agreed so it could be disclosed,
Expansion of business plans of the Valluarix team in late 2019
Statements on Brexit and NICE lodgement

This year were simple bullet points on aspirations
a. clinical progress in vitiligo;
b. complementary OTC product(s);
c. a new indication;
d. investigation of DNA repair;
e. expansion of R&D;
f. US market access;
g. Australian TGA submission accepted, initiation of the review; and
h. European market expansion.

Does not seem to matter though, market has been pretty positive today.
Maybe some investors got a debrief at the JP Morgan Health Care conference yesterday.
Attached Image


Said 'Thanks' for this post: oystercatcher  andymen  xlnja  Frogster  royco  
 
Johnny H
post Posted: Yesterday, 10:03 AM
  Quote Post


Posts: 846
Thanks: 1541


In Reply To: macgyver's post @ Yesterday, 08:35 AM

Clinuvel will need to conduct a bridging study before they can file a new drug application in Japan. To my knowledge, they have not done so.



--------------------
Clinuvel until my bowels release for the last time.

Said 'Thanks' for this post: macgyver  royco  
 
macgyver
post Posted: Yesterday, 08:35 AM
  Quote Post


Posts: 698
Thanks: 673


I noticed the Japanese application was missing from the to-do list. Conspicuous or lodging in 2021?

 
blackm3
post Posted: Yesterday, 07:38 AM
  Quote Post


Posts: 318
Thanks: 458


In Reply To: bretto32's post @ Yesterday, 07:24 AM

Cheers and signed


Said 'Thanks' for this post: bretto32  
 
 


4867 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING